Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTX-7739 single ascending dose study in healthy volunteers
NL-OMON49863Phase 1Completed
- Sponsor
- Yumanity Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing YTX-7739 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events. Started Sep 2019; status: completed.
02
Drugs
YTX-7739
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON49863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49863.